Bal Pharma Limited has announced the newspaper publication of its abridged Unaudited Standalone and Consolidated financial results for the quarter and financial year ended 31 March 2025. These results, which were approved by the Board of Directors on 29 May 2025, were published in Financial Express (English) and Sanjay vani (Kannada) on 31 May 2025.
Key financial highlights (figures in rupees, Lakhs, or Crore where applicable):
- Total Income from operations (Net):
- For the quarter ended 31 March 2025: ₹70.49 crore (₹7048.96 Lakhs)
- For the quarter ended 31 March 2024: ₹73.06 crore (₹7306.33 Lakhs)
- For the financial year ended 31 March 2025: ₹279.71 crore (₹27971.46 Lakhs)
- For the financial year ended 31 March 2024: ₹282.50 crore (₹28249.71 Lakhs)
- Net Profit/(Loss) for the period (after tax):
- For the quarter ended 31 March 2025: Loss of ₹0.07 crore (₹7.33 Lakhs)
- For the quarter ended 31 March 2024: Loss of ₹0.03 crore (₹2.97 Lakhs)
- For the financial year ended 31 March 2025: Loss of ₹1.42 crore (₹142.49 Lakhs)
- For the financial year ended 31 March 2024: Loss of ₹0.15 crore (₹15.22 Lakhs)
- Earnings Per Share (EPS) (Basic & Diluted):
- For the quarter ended 31 March 2025: (₹0.05)
- For the quarter ended 31 March 2024: (₹0.02)
- For the financial year ended 31 March 2025: (₹0.98)
- For the financial year ended 31 March 2024: (₹0.10)
The company submitted these newspaper advertisements to the exchanges in compliance with Regulation 47 of SEBI (LODR) Regulations, 2015.